At the news
? MIXEDIMPACT 5/10 CLUSTER filed Apr 30, 2026 at 17:22 ET
Anika Therapeutics insiders (CEO and director) purchased $223K in open-market shares in the week following the Q1 2026 earnings release. Revenue of $29.6M beat consensus but GAAP EPS of -$0.37 missed estimates. The insider buying suggests confidence in the company's outlook, but the EPS miss tempers enthusiasm.
- CEO Stephen Griffin purchased 12,200 shares for ~$150K at $12.29 on April 30.
- Director John Henneman III purchased 5,000 shares for ~$73K at $14.66 on May 1.
- Q1 2026 revenue $29.6M (+13% YoY) beat consensus of $28.1M.
- Q1 2026 GAAP EPS -$0.37 missed consensus -$0.21, with $4.9M in severance costs.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access